Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:36:06 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:CPRX from 2023-05-07 to 2024-05-06 - 37 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 08:00U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
2024-04-22 08:00U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
2024-03-28 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
2024-03-27 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
2024-03-13 07:55U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces AGAMREE(TM) Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
2024-03-05 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
2024-02-28 18:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-27 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
2024-02-21 09:00U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical ¢ € ™s VISION-DMD Vamorolone (AGAMREE ‚ ®) Study Results in the Peer-Reviewed Journal Neurology
2024-02-14 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2024-01-09 16:05U:CPRXNews ReleaseCatalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
2024-01-05 08:02U:CPRXNews ReleaseCatalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
2024-01-04 16:50U:CPRXNews ReleaseCatalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2023-12-18 06:30U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces FIRDAPSE ‚ ® New Drug Application Submitted in Japan by Partner DyDo Pharma
2023-12-05 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
2023-12-04 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
2023-11-16 08:05U:CPRXNews ReleaseCatalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
2023-11-08 16:11U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
2023-11-02 10:38U:CPRXNews ReleaseCatalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE ‚ ®
2023-10-30 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
2023-10-26 15:19U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports FDA Approval of AGAMREE ‚ ® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
2023-10-23 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
2023-10-19 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
2023-10-16 08:03U:CPRXNews ReleasePatrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
2023-10-13 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE ‚ ®
2023-09-18 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
2023-08-16 10:57U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
2023-08-14 08:05U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA ‚ ® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
2023-08-09 16:17U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-25 08:03U:CPRXNews ReleasePatrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
2023-07-24 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
2023-07-19 06:00U:CPRXNews ReleaseCatalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
2023-06-20 06:00U:CPRXNews ReleaseCatalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
2023-06-01 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
2023-05-30 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
2023-05-10 16:28U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
2023-05-09 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE ‚ ® From 80 mg Per Day To 100 mg Per Day